SUMMARY, EXPLANATION AND LIMITATIONS:
This monoclonal antibodies cocktail recognize two different epitopes from a 118 amino acids protein which is fundamentally localized in endoplasmic reticule, Golgi apparatus and melanocyte melanosomes. The protein MART-1 (Melanoma antigen recognized by T cells 1) or Melan-A, after its migration in proteasome and transporting through the TAP system, is specifically recognized by positive CD8 T cells which are generated in the inflammatory infiltrate present in most melanomas. Nowadays it is active working in the possibility of generate induced responses or through vaccines with Melan-A derived peptides for controlling the malignant melanoma, a fact which reaffirms the importance of determinating in vitro the presence of this marker in each case. The antibodies cocktail reacts with human and horse Melan-A protein, not having been tested in other species.
Immunogen: Recombinant MART-1 protein.
Staining pattern: Cytoplasmic.
Positive control: Tissue sample from human melanoma.
This antibody is designed for the specific localization of human Melan-A using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
This monoclonal antibodies cocktail recognize either normal melanocytes or nevus melanocytic cells and melanoma. Therefore it is a cell line marker, not of benignant or malignant process. However, this cocktail against Melan-A is extremely sensitive for detecting melanic tumorous cells, especially in quick immunohistochemical procedures, which currently are used for detecting micrometastasis in sentinel lymph nodes. The product does not react with tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.